Open AccessP548: BEMCENTINIB COMBINED WITH LOW‐DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)
Author(s) -
Loges S.,
Heuser M.,
Chromik J.,
Sutamtewagul G.,
KappSchwoerer S.,
Crugnola M.,
Di Renzo N.,
Lemoli R.,
Mattei D.,
BenBatalla I.,
Waizenegger J.,
Rieckmann L.M.,
Janning M.,
Imbusch C. D.,
Beumer N.,
Micklem D.,
GorceaCarson C.,
Lawson G.,
Nautiyal J.,
Deharo S.,
Fiedler W.,
AlvaradoValero Y.,
Gjertsen B.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845080.27665.da
Subject(s) - medicine , cytarabine , oncology , bone marrow , population , chemotherapy , clinical trial , biomarker , biology , biochemistry , environmental health